Evaluation of the Efficacy of the Sequencing Method by Gene-panel, Compared to the Reference Sanger Method, on Patients With Primary Immuno-deficiencies, and Who Need a Genetic Diagnosis.
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 115
- 试验地点
- 2
- 主要终点
- Comparison of the 2 sequencing methods
研究概览
简要总结
In order to accelerate the identification of genes responsibles of PID, and to improve the diagnosis of PID, the research team would like to validate a rapid and targeted method of high-throughput sequencing, on 301 genes, known to be involved in PID.
详细描述
The Primary Immuno-Deficiencies (PID) are a set of rare diseases (estimated incidence of 1/5000). Today, more than 320 PID are described, and for 301 of them, the genetic cause has been identified, which underlines the huge diversity of all PID.
The genetic diagnosis of PID is very important for the comprehension of PID physiopathology, their treatment and the genetic patient information.
The characterisation of the clinical and immunological phenotype of patients allowed to identify a known morbid gene in 30% of cases, but for other patients, the genetic cause remains unknown, due to, inter alia, the lack of efficient tools for genetic exploration.
In this context, each year, around 600 French and foreign patients are explored at the Necker hospital CEDI (Center for Immuno-Deficiencies Explorations), for whom are identified, in 30% of cases, a known genetic cause.
Their treatment and the diagnosis of these patients is slow, partially because these studies are dependants of research fundings. In addition, in the current practice, the investigators sometimes discover incidental findings via the non-targeted high throughput genetic analyzes.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- — 至 70 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient who need a genetic diagnosis of PID done at Necker's CEDI (Center for Immuno-Deficiencies Explorations), in the frame of an initial causal mutation identification
- •Patient having signed an informed consent form (or parents for minor patients)
- •Patient affiliated to National Health Care Insurance
排除标准
- •Patient refusing to participate
- •Patient under legal guardianship
- •Patient that can't fulfill the study requirements, for any geographic, social or psychic reason
研究组 & 干预措施
Patient with PID
For patient with clinical diagnosis of PID, an additional blood sampling will be taken.
The genetic diagnosis will be done via the method of gene-panel in the frame of the study.
A genetic confirmation will, in any case, be done via the reference method (Sanger), in order to establish a final diagnosis for these patients.
干预措施: Blood sampling (Biological)
结局指标
主要结局
Comparison of the 2 sequencing methods
时间窗: 2 years
Assess the efficacy of the identification of the genetic cause of PID, via the high throughput gene panel sequencing method, compared to the reference Sanger method, on patients with no identified mutation after analyzes done by available technics on hospital laboratories.
次要结局
未报告次要终点